$PHVS

Nijdam Anna sold $82K of PHVS

Nijdam Anna (Principal Accounting Officer) sold 2,670 shares of Pharvaris N.V. (PHVS) at $30.87 on 2026-06-04.

Original reporting
SEC EDGAR · Nijdam Anna
Published Jun 8, 2026, 6:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by a named officer, which can marginally affect sentiment but does not provide operational or financial guidance.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it is unlikely to drive a fundamental repricing alone.

03

What to watch

Check whether there are additional insider transactions around the same period and whether the insider’s remaining holdings materially change over subsequent filings.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-08)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

SEC Form 4 shows PHVS principal accounting officer Nijdam Anna sold 2,670 shares in an open-market transaction for ~$82.4K.

Expected impact

Low near-term impact; any effect is likely short-lived unless selling accelerates or coincides with other negative news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is a relatively small dollar amount and does not indicate a new company event (no guidance, trial, deal, or enforcement action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially with no 10b5-1 plan disclosed.

Key entities

  • Pharvaris N.V.

    Company whose insider transaction was reported on SEC Form 4.

  • Nijdam Anna

    Principal Accounting Officer who sold 2,670 PHVS shares.

Related articles

MedAI 8/10

Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).